Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025

Core Insights - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and announced four abstract presentations at the upcoming AASLD The Liver Meeting® 2025 [1][6] Presentation Details - The first abstract compares digital images versus glass slides for histopathological evaluation of liver biopsy samples in the NATiV3 study, scheduled for presentation on November 8, 2025 [2][3] - The second abstract discusses continuous digital pathology scoring revealing fibrosis reversal and therapeutic benefits of lanifibranor, with a presentation date of November 9, 2025 [2] - The third abstract highlights high-resolution digital pathology demonstrating antifibrotic and anti-inflammatory effects of lanifibranor in TAA-induced cirrhotic rodent models, also on November 9, 2025 [2] - The fourth abstract combines digital pathology and biomarkers to quantify fibrosis and treatment response to lanifibranor in a TAA-induced cirrhosis model, presented on November 9, 2025 [2] About Lanifibranor - Lanifibranor is Inventiva's lead product candidate, an orally available small molecule that activates all three PPAR isoforms, inducing anti-fibrotic and anti-inflammatory effects [5][6] - It is the only pan-PPAR agonist in clinical development for MASH, with the FDA granting Breakthrough Therapy and Fast Track designations [5] Company Overview - Inventiva is a public company listed on Euronext Paris and NASDAQ, focusing on the research and development of oral small molecule therapies for MASH [6][7]